HANSOH PHARMA ANNOUNCES STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ROCHE TO ADVANCE NOVEL ADC PORTFOLIO
- The collaboration will advance a broad antibody-drug conjugate (ADC) portfolio across multiple cancer types.
- Hansoh Pharma is eligible to receive an upfront payment of US$400 million, a first anniversary payment of US$110 million and potentially more than US$15 billion milestone payments, as well as royalties on potential future product sales.SHANGHAI, October 19, 2026—Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that it has entered into a strategic collaboration and license agreement with Roche. This agreement marks the second collaboration between the two companies in the antibody-drug conjugate (ADC) field, building on a solid and productive relationship leveraging the two groups' deep expertise, Hansoh and Roche will accelerate the global development of novel ADC programs and bring them to patients worldwide.
The strategic collaboration spans a broad portfolio of ADC programs, comprising two preclinical Hansoh ADC programs and multiple ADC programs based on Roche-proposed targets powered by Hansoh’s proprietary ADC technology platform.
Under the collaboration agreement, Hansoh will lead the early development of the programs up to the completion of global PhaseⅠa clinical trials. Roche will be responsible for further developing the programs worldwide (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan). Hansoh will retain all rights to develop, register and commercialize the programs within the Chinese Mainland, Hong Kong, Macau and Taiwan.
Hansoh will receive an upfront payment of US$400 million as well as a first anniversary payment of US$110 million, and be eligible to receive potentially more than US$15 billion in milestone payments associated with the development, regulatory approval and commercialization of the programs, as well as tiered royalties on potential future product sales. Under this agreement, Hansoh has the option to select up to two programs and contribute to their development outside the Chinese Mainland, Hong Kong, Macau and Taiwan and, in return for such contribution, become eligible to receive incremental upside from the commercialization of these two programs in the United States.
Eliza Sun, Executive Director of the Board, Hansoh Pharma, said: “Building on the ADC partnership we announced last year, we are delighted to further strengthen our collaboration with Roche. This new agreement reflects our shared commitment to advancing ADC innovation and underscores our strategy of leveraging our deep expertise to accelerate the development of transformative therapies for cancer patients globally.”
“Expanding our strategic collaboration with Hansoh marks an important step in advancing our ADC vision. Exploring next generation ADCs is one of the most compelling frontiers in oncology today, offering the opportunity to address critical unmet needs and accelerate potential therapies for patients worldwide”, said Boris L. Zaïtra, Head of Corporate Business Development at Roche.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
